drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01390 | DB01602 | 1,117 | 339 | [
"DDInter1683",
"DDInter159"
] | Sodium bicarbonate | Bacampicillin | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal ac... | Moderate | 1 | [
[
[
1117,
24,
339
]
],
[
[
1117,
63,
1096
],
[
1096,
24,
339
]
],
[
[
1117,
62,
752
],
[
752,
24,
339
]
],
[
[
1117,
62,
663
],
[
663,
... | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacampicillin"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophen... | Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Bacampicillin
Sodium bicarbonate may cause a minor interaction that can limit clinical effects when t... |
DB00241 | DB01234 | 288 | 1,220 | [
"DDInter257",
"DDInter513"
] | Butalbital | Dexamethasone | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
288,
24,
1220
]
],
[
[
288,
24,
870
],
[
870,
1,
1220
]
],
[
[
288,
24,
175
],
[
175,
40,
1220
]
],
[
[
288,
62,
168
],
[
168,
2... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dex... |
DB09472 | DB11915 | 1,383 | 1,293 | [
"DDInter1693",
"DDInter1909"
] | Sodium sulfate | Valbenazine | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
1383,
24,
1293
]
],
[
[
1383,
63,
521
],
[
521,
24,
1293
]
],
[
[
1383,
64,
1557
],
[
1557,
24,
1293
]
],
[
[
1383,
24,
927
],
[
927,
... | [
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
... | Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Sodium sulfate may lead to a major life threatening interaction when taken with Astemizole and Astemizole may... |
DB00734 | DB00747 | 1,664 | 1,442 | [
"DDInter1605",
"DDInter1647"
] | Risperidone | Scopolamine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
1664,
24,
1442
]
],
[
[
1664,
63,
19
],
[
19,
24,
1442
]
],
[
[
1664,
6,
4973
],
[
4973,
45,
1442
]
],
[
[
1664,
21,
29326
],
[
29326,... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Risperidone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Scopolamine (Compound)
Risperidone (C... |
DB00363 | DB08897 | 695 | 1,429 | [
"DDInter419",
"DDInter22"
] | Clozapine | Aclidinium | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
695,
24,
1429
]
],
[
[
695,
63,
352
],
[
352,
24,
1429
]
],
[
[
695,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
695,
6,
4304
],
[
4304,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
... | Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate... |
DB12001 | DB12147 | 564 | 241 | [
"DDInter7",
"DDInter661"
] | Abemaciclib | Erdafitinib | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Moderate | 1 | [
[
[
564,
24,
241
]
],
[
[
564,
64,
384
],
[
384,
24,
241
]
],
[
[
564,
24,
982
],
[
982,
63,
241
]
],
[
[
564,
63,
578
],
[
578,
24,... | [
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Abemaciclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelali... | Abemaciclib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cau... |
DB01233 | DB01362 | 1,311 | 497 | [
"DDInter1197",
"DDInter960"
] | Metoclopramide | Iohexol | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1311,
25,
497
]
],
[
[
1311,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1311,
63,
494
],
[
494,
24,
497
]
],
[
[
1311,
64,
999
],
[
999,
... | [
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Metoclopramide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is ... | Metoclopramide (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases ... |
DB00495 | DB08885 | 139 | 363 | [
"DDInter1961",
"DDInter33"
] | Zidovudine | Aflibercept | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Moderate | 1 | [
[
[
139,
24,
363
]
],
[
[
139,
24,
1531
],
[
1531,
24,
363
]
],
[
[
139,
63,
58
],
[
58,
24,
363
]
],
[
[
139,
24,
384
],
[
384,
63,... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
... | Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alef... |
DB00675 | DB09039 | 888 | 1,670 | [
"DDInter1744",
"DDInter629"
] | Tamoxifen | Eliglustat | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
888,
25,
1670
]
],
[
[
888,
24,
479
],
[
479,
23,
1670
]
],
[
[
888,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
888,
64,
121
],
[
121,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may c... |
DB00928 | DB10316 | 1,426 | 334 | [
"DDInter148",
"DDInter1248"
] | Azacitidine | Mumps virus strain B level jeryl lynn live antigen | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1426,
25,
334
]
],
[
[
1426,
64,
1057
],
[
1057,
25,
334
]
],
[
[
1426,
25,
908
],
[
908,
25,
334
]
],
[
[
1426,
63,
599
],
[
599,
... | [
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Azacitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Azacitidine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Azacitidine may lead to a major life threatening interaction when taken with Golimumab and Golimumab ... |
DB00530 | DB12267 | 1,195 | 1,476 | [
"DDInter667",
"DDInter233"
] | Erlotinib | Brigatinib | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1195,
24,
1476
]
],
[
[
1195,
24,
800
],
[
800,
24,
1476
]
],
[
[
1195,
25,
379
],
[
379,
24,
1476
]
],
[
[
1195,
63,
79
],
[
79,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Erlotinib may lead to a major life threatening interaction when taken with Rabeprazole and Rabeprazole may cause a ... |
DB00635 | DB00812 | 1,573 | 998 | [
"DDInter1515",
"DDInter1451"
] | Prednisone | Phenylbutazone | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
1573,
24,
998
]
],
[
[
1573,
23,
307
],
[
307,
1,
998
]
],
[
[
1573,
63,
362
],
[
362,
1,
998
]
],
[
[
1573,
24,
97
],
[
97,
40,... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Prednisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Phenylbutazone (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenylbutazone (Compound... |
DB00261 | DB04932 | 702 | 1,564 | [
"DDInter93",
"DDInter491"
] | Anagrelide | Defibrotide | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Major | 2 | [
[
[
702,
25,
1564
]
],
[
[
702,
23,
297
],
[
297,
62,
1564
]
],
[
[
702,
24,
914
],
[
914,
24,
1564
]
],
[
[
702,
25,
1100
],
[
1100,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may caus... |
DB00486 | DB00497 | 1,614 | 828 | [
"DDInter1253",
"DDInter1366"
] | Nabilone | Oxycodone | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Moderate | 1 | [
[
[
1614,
24,
828
]
],
[
[
1614,
63,
421
],
[
421,
1,
828
]
],
[
[
1614,
24,
314
],
[
314,
1,
828
]
],
[
[
1614,
24,
560
],
[
560,
4... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxycodone (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine (Compound) resembles Oxycodone (Compound)
... |
DB01095 | DB06589 | 671 | 1,250 | [
"DDInter769",
"DDInter1400"
] | Fluvastatin | Pazopanib | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
671,
24,
1250
]
],
[
[
671,
6,
15333
],
[
15333,
45,
1250
]
],
[
[
671,
7,
3553
],
[
3553,
46,
1250
]
],
[
[
671,
18,
4374
],
[
4374,
... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Fluvastatin",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound... | Fluvastatin (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Pazopanib (Compound)
Fluvastatin (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Pazopanib (Compound)
Fluvastatin (Compound) downregulates SDHB (Gene) and SDHB (Gene) is upregulated by Pazopanib (Compound)
Fluvastatin (Com... |
DB00794 | DB12500 | 759 | 283 | [
"DDInter1521",
"DDInter714"
] | Primidone | Fedratinib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
759,
25,
283
]
],
[
[
759,
25,
466
],
[
466,
62,
283
]
],
[
[
759,
25,
351
],
[
351,
23,
283
]
],
[
[
759,
64,
1419
],
[
1419,
2... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u}... | Primidone may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Primidone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interac... |
DB06788 | DB11057 | 1,616 | 720 | [
"DDInter864",
"DDInter1223"
] | Histrelin | Mineral oil | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1616,
24,
720
]
],
[
[
1616,
24,
927
],
[
927,
63,
720
]
],
[
[
1616,
63,
1151
],
[
1151,
24,
720
]
],
[
[
1616,
64,
1069
],
[
1069,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Suniti... |
DB04896 | DB06704 | 901 | 247 | [
"DDInter1220",
"DDInter952"
] | Milnacipran | Iobenguane (I-131) | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
901,
37,
247
]
],
[
[
901,
6,
7390
],
[
7390,
45,
247
]
],
[
[
901,
21,
28787
],
[
28787,
60,
247
]
],
[
[
901,
24,
1090
],
[
1090,
... | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Milnacipran",
"{u} (Compound) binds {v} (Gene)",
"SLC6... | Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Milnacipran may lead to a major life threatening interaction when taken with Iobenguane
Milnacipran (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Milnacipran (Compound) causes ... |
DB08932 | DB09098 | 1,398 | 98 | [
"DDInter1111",
"DDInter1700"
] | Macitentan | Somatrem | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1398,
24,
98
]
],
[
[
1398,
24,
159
],
[
159,
63,
98
]
],
[
[
1398,
64,
609
],
[
609,
24,
98
]
],
[
[
1398,
63,
868
],
[
868,
24... | [
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Macitentan may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromyci... |
DB00363 | DB15091 | 695 | 676 | [
"DDInter419",
"DDInter1901"
] | Clozapine | Upadacitinib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
695,
25,
676
]
],
[
[
695,
25,
283
],
[
283,
24,
676
]
],
[
[
695,
64,
600
],
[
600,
24,
676
]
],
[
[
695,
24,
98
],
[
98,
24,
... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} m... | Clozapine may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Clozapine may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate in... |
DB00400 | DB08875 | 353 | 1,618 | [
"DDInter843",
"DDInter262"
] | Griseofulvin | Cabozantinib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
353,
24,
1618
]
],
[
[
353,
24,
1135
],
[
1135,
62,
1618
]
],
[
[
353,
24,
723
],
[
723,
24,
1618
]
],
[
[
353,
24,
384
],
[
384,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Apre... |
DB00313 | DB00434 | 556 | 13 | [
"DDInter1913",
"DDInter459"
] | Valproic acid | Cyproheptadine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
556,
24,
13
]
],
[
[
556,
24,
104
],
[
104,
63,
13
]
],
[
[
556,
6,
16431
],
[
16431,
45,
13
]
],
[
[
556,
5,
11610
],
[
11610,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Valproic acid (Compound) binds UGT1A3 (Gene) and UGT1A3 (Gene) is bound by Cyproheptadine (Compound)
... |
DB00285 | DB00637 | 1,100 | 1,557 | [
"DDInter1927",
"DDInter128"
] | Venlafaxine | Astemizole | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Moderate | 1 | [
[
[
1100,
24,
1557
]
],
[
[
1100,
6,
8374
],
[
8374,
45,
1557
]
],
[
[
1100,
23,
112
],
[
112,
62,
1557
]
],
[
[
1100,
24,
770
],
[
770,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Astemizole"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Venlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Astemizole (Compound)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Astemizole
Venlafaxine ma... |
DB01591 | DB08881 | 667 | 868 | [
"DDInter1696",
"DDInter1925"
] | Solifenacin | Vemurafenib | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
667,
25,
868
]
],
[
[
667,
6,
8374
],
[
8374,
45,
868
]
],
[
[
667,
21,
28847
],
[
28847,
60,
868
]
],
[
[
667,
62,
112
],
[
112,
... | [
[
[
"Solifenacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Solifenacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemu... | Solifenacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Solifenacin (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidaz... |
DB06674 | DB09121 | 908 | 1,328 | [
"DDInter837",
"DDInter140"
] | Golimumab | Aurothioglucose | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
908,
24,
1328
]
],
[
[
908,
63,
367
],
[
367,
24,
1328
]
],
[
[
908,
64,
581
],
[
581,
24,
1328
]
],
[
[
908,
25,
310
],
[
310,
... | [
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Golimumab may lead to a major life threatening interaction when taken with Infliximab an... |
DB00421 | DB01142 | 443 | 1,264 | [
"DDInter1707",
"DDInter593"
] | Spironolactone | Doxepin | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
443,
24,
1264
]
],
[
[
443,
24,
401
],
[
401,
24,
1264
]
],
[
[
443,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
443,
21,
28954
],
[
28954,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Spironolactone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Spironolactone... |
DB00078 | DB00495 | 1,172 | 139 | [
"DDInter898",
"DDInter1961"
] | Ibritumomab tiuxetan | Zidovudine | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Moderate | 1 | [
[
[
1172,
24,
139
]
],
[
[
1172,
24,
810
],
[
810,
63,
139
]
],
[
[
1172,
25,
405
],
[
405,
63,
139
]
],
[
[
1172,
24,
599
],
[
599,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stronti... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine
Ibritumomab tiuxetan may lead to a major life threatening interaction when... |
DB01142 | DB01244 | 1,264 | 762 | [
"DDInter593",
"DDInter192"
] | Doxepin | Bepridil | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Major | 2 | [
[
[
1264,
25,
762
]
],
[
[
1264,
74,
1376
],
[
1376,
24,
762
]
],
[
[
1264,
64,
704
],
[
704,
1,
762
]
],
[
[
1264,
63,
832
],
[
832,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
]
],
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphen... | Doxepin (Compound) resembles Diphenhydramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Bepridil
Doxepin may lead to a major life threatening in... |
DB00738 | DB09045 | 485 | 52 | [
"DDInter1420",
"DDInter607"
] | Pentamidine | Dulaglutide | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
485,
24,
52
]
],
[
[
485,
24,
170
],
[
170,
23,
52
]
],
[
[
485,
24,
609
],
[
609,
24,
52
]
],
[
[
485,
25,
1154
],
[
1154,
24,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and... |
DB00757 | DB15093 | 1,166 | 1,654 | [
"DDInter581",
"DDInter1698"
] | Dolasetron | Somapacitan | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1166,
24,
1654
]
],
[
[
1166,
25,
351
],
[
351,
24,
1654
]
],
[
[
1166,
64,
1010
],
[
1010,
24,
1654
]
],
[
[
1166,
24,
159
],
[
159,
... | [
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribocicli... | Dolasetron may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Dolasetron may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate int... |
DB00445 | DB12267 | 322 | 1,476 | [
"DDInter655",
"DDInter233"
] | Epirubicin | Brigatinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
322,
24,
1476
]
],
[
[
322,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
322,
63,
168
],
[
168,
23,
1476
]
],
[
[
322,
63,
1184
],
[
1184,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortez... |
DB04845 | DB10429 | 309 | 200 | [
"DDInter1001",
"DDInter282"
] | Ixabepilone | Candida albicans | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
309,
24,
200
]
],
[
[
309,
24,
1683
],
[
1683,
24,
200
]
],
[
[
309,
25,
976
],
[
976,
24,
200
]
],
[
[
309,
63,
168
],
[
168,
2... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Ixabepilone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitini... |
DB11817 | DB13007 | 1,259 | 1,060 | [
"DDInter165",
"DDInter642"
] | Baricitinib | Enfortumab vedotin | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Major | 2 | [
[
[
1259,
25,
1060
]
],
[
[
1259,
25,
270
],
[
270,
24,
1060
]
],
[
[
1259,
64,
350
],
[
350,
24,
1060
]
],
[
[
1259,
63,
810
],
[
810,
... | [
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
... | Baricitinib may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Baricitinib may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a... |
DB00501 | DB01193 | 752 | 819 | [
"DDInter380",
"DDInter12"
] | Cimetidine | Acebutolol | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
752,
24,
819
]
],
[
[
752,
24,
887
],
[
887,
1,
819
]
],
[
[
752,
63,
88
],
[
88,
1,
819
]
],
[
[
752,
6,
12523
],
[
12523,
45,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Acebutolol (Compound)
Cime... |
DB00087 | DB09312 | 599 | 967 | [
"DDInter41",
"DDInter103"
] | Alemtuzumab | Antilymphocyte immunoglobulin (horse) | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Moderate | 1 | [
[
[
599,
24,
967
]
],
[
[
599,
24,
1683
],
[
1683,
24,
967
]
],
[
[
599,
24,
1531
],
[
1531,
63,
967
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Antilymphocyte immunoglobulin (horse)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when t... |
DB00683 | DB11767 | 1,382 | 1,583 | [
"DDInter1212",
"DDInter1643"
] | Midazolam | Sarilumab | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
1382,
24,
1583
]
],
[
[
1382,
24,
1362
],
[
1362,
24,
1583
]
],
[
[
1382,
25,
384
],
[
384,
24,
1583
]
],
[
[
1382,
63,
58
],
[
58,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Midazolam may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moder... |
DB00322 | DB11943 | 141 | 255 | [
"DDInter742",
"DDInter495"
] | Floxuridine | Delafloxacin | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Minor | 0 | [
[
[
141,
23,
255
]
],
[
[
141,
24,
1001
],
[
1001,
23,
255
]
],
[
[
141,
63,
377
],
[
377,
23,
255
]
],
[
[
141,
35,
1238
],
[
1238,
... | [
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Delafloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
],
... | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin... |
DB00189 | DB00748 | 459 | 662 | [
"DDInter691",
"DDInter297"
] | Ethchlorvynol | Carbinoxamine | Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
459,
24,
662
]
],
[
[
459,
24,
1594
],
[
1594,
24,
662
]
],
[
[
459,
24,
407
],
[
407,
63,
662
]
],
[
[
459,
25,
475
],
[
475,
2... | [
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Op... |
DB09074 | DB11901 | 1,362 | 913 | [
"DDInter1327",
"DDInter107"
] | Olaparib | Apalutamide | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1362,
25,
913
]
],
[
[
1362,
63,
608
],
[
608,
23,
913
]
],
[
[
1362,
24,
110
],
[
110,
62,
913
]
],
[
[
1362,
63,
1322
],
[
1322,
... | [
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Pola... |
DB00047 | DB01203 | 176 | 699 | [
"DDInter932",
"DDInter1255"
] | Insulin glargine | Nadolol | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
176,
24,
699
]
],
[
[
176,
24,
729
],
[
729,
1,
699
]
],
[
[
176,
24,
1152
],
[
1152,
23,
699
]
],
[
[
176,
24,
609
],
[
609,
62... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine may cause a minor interaction ... |
DB00741 | DB08822 | 167 | 911 | [
"DDInter885",
"DDInter156"
] | Hydrocortisone | Azilsartan medoxomil | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
167,
24,
911
]
],
[
[
167,
63,
217
],
[
217,
1,
911
]
],
[
[
167,
21,
29081
],
[
29081,
60,
911
]
],
[
[
167,
24,
1450
],
[
1450,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesarta... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Hydrocortisone (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Azilsartan medoxomil (Compound)
Hydrocortisone... |
DB00607 | DB01024 | 1,249 | 1,096 | [
"DDInter1256",
"DDInter1252"
] | Nafcillin | Mycophenolic acid | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
1249,
24,
1096
]
],
[
[
1249,
7,
3422
],
[
3422,
46,
1096
]
],
[
[
1249,
21,
28996
],
[
28996,
60,
1096
]
],
[
[
1249,
23,
609
],
[
60... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Nafcillin",
"{u} (Compound) upregulates {v} (Gene)",
"SATB1"
],
[
"SATB1",
"{u} (Gene) is upregulated by {... | Nafcillin (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Mycophenolic acid (Compound)
Nafcillin (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Mycophenolic acid (Compound)
Nafcillin may cause a minor interaction that can limit... |
DB04865 | DB06372 | 4 | 259 | [
"DDInter1335",
"DDInter1594"
] | Omacetaxine mepesuccinate | Rilonacept | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
4,
24,
259
]
],
[
[
4,
63,
0
],
[
0,
24,
259
]
],
[
[
4,
24,
1619
],
[
1619,
63,
259
]
],
[
[
4,
24,
478
],
[
478,
24,
259... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases whe... |
DB00196 | DB06176 | 600 | 1,342 | [
"DDInter743",
"DDInter1616"
] | Fluconazole | Romidepsin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
600,
24,
1342
]
],
[
[
600,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
600,
24,
336
],
[
336,
24,
1342
]
],
[
[
600,
24,
1616
],
[
1616,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine ... |
DB01599 | DB09268 | 1,232 | 1,662 | [
"DDInter1523",
"DDInter1464"
] | Probucol | Picosulfuric acid | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1232,
24,
1662
]
],
[
[
1232,
24,
484
],
[
484,
63,
1662
]
],
[
[
1232,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
1232,
24,
1491
],
[
1491... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
... | Probucol may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Probucol may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib m... |
DB00912 | DB06589 | 473 | 1,250 | [
"DDInter1581",
"DDInter1400"
] | Repaglinide | Pazopanib | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
473,
24,
1250
]
],
[
[
473,
6,
15333
],
[
15333,
45,
1250
]
],
[
[
473,
18,
5245
],
[
5245,
57,
1250
]
],
[
[
473,
21,
28658
],
[
2865... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound... | Repaglinide (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Pazopanib (Compound)
Repaglinide (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Pazopanib (Compound)
Repaglinide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
... |
DB00108 | DB09331 | 1,066 | 745 | [
"DDInter1268",
"DDInter478"
] | Natalizumab | Daratumumab | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Major | 2 | [
[
[
1066,
25,
745
]
],
[
[
1066,
25,
139
],
[
139,
24,
745
]
],
[
[
1066,
25,
287
],
[
287,
63,
745
]
],
[
[
1066,
64,
599
],
[
599,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u... | Natalizumab may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may ca... |
DB00701 | DB01611 | 1,091 | 1,487 | [
"DDInter90",
"DDInter893"
] | Amprenavir | Hydroxychloroquine | Amprenavir is a protease inhibitor used to treat HIV infection. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1091,
24,
1487
]
],
[
[
1091,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
1091,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
1091,
63,
723
],
[
... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Com... | Amprenavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Amprenavir (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Aprep... |
DB00468 | DB00543 | 1,424 | 87 | [
"DDInter1557",
"DDInter82"
] | Quinine | Amoxapine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
1424,
24,
87
]
],
[
[
1424,
24,
623
],
[
623,
40,
87
]
],
[
[
1424,
64,
695
],
[
695,
40,
87
]
],
[
[
1424,
63,
867
],
[
867,
1,... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"Qu... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Quinine may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Amoxapine (Compound)
Quinine may cause a moder... |
DB00694 | DB09330 | 51 | 985 | [
"DDInter485",
"DDInter1352"
] | Daunorubicin | Osimertinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
51,
25,
985
]
],
[
[
51,
23,
1247
],
[
1247,
23,
985
]
],
[
[
51,
24,
1478
],
[
1478,
24,
985
]
],
[
[
51,
63,
134
],
[
134,
24,... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Daunorubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"S... | Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ivacafto... |
DB00491 | DB09128 | 127 | 1,241 | [
"DDInter1217",
"DDInter231"
] | Miglitol | Brexpiprazole | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
127,
24,
1241
]
],
[
[
127,
24,
1296
],
[
1296,
63,
1241
]
],
[
[
127,
63,
1179
],
[
1179,
24,
1241
]
],
[
[
127,
24,
959
],
[
959,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Insulin li... |
DB00475 | DB00619 | 1,119 | 1,419 | [
"DDInter355",
"DDInter909"
] | Chlordiazepoxide | Imatinib | An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
1119,
24,
1419
]
],
[
[
1119,
6,
12523
],
[
12523,
45,
1419
]
],
[
[
1119,
24,
222
],
[
222,
62,
1419
]
],
[
[
1119,
64,
475
],
[
475,... | [
[
[
"Chlordiazepoxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Chlordiazepoxide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (C... | Chlordiazepoxide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Imatinib (Compound)
Chlordiazepoxide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Imatinib
Chlordiaze... |
DB11817 | DB12159 | 1,259 | 12 | [
"DDInter165",
"DDInter609"
] | Baricitinib | Dupilumab | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that indu... | Major | 2 | [
[
[
1259,
25,
12
]
],
[
[
1259,
62,
1461
],
[
1461,
23,
12
]
],
[
[
1259,
64,
599
],
[
599,
24,
12
]
],
[
[
1259,
63,
1136
],
[
1136,
... | [
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Baricitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Baricitinib may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dupilumab
Baricitinib may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a m... |
DB01344 | DB06723 | 1,231 | 115 | [
"DDInter1830",
"DDInter58"
] | Tolevamer | Aluminum hydroxide | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Major | 2 | [
[
[
1231,
25,
115
]
],
[
[
1231,
24,
1482
],
[
1482,
23,
115
]
],
[
[
1231,
63,
1252
],
[
1252,
23,
115
]
],
[
[
1231,
24,
624
],
[
624,
... | [
[
[
"Tolevamer",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digit... | Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin... |
DB08875 | DB12095 | 1,618 | 179 | [
"DDInter262",
"DDInter1760"
] | Cabozantinib | Telotristat ethyl | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1618,
24,
179
]
],
[
[
1618,
64,
79
],
[
79,
24,
179
]
],
[
[
1618,
24,
214
],
[
214,
24,
179
]
],
[
[
1618,
25,
1468
],
[
1468,
... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"... | Cabozantinib may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatin... |
DB00262 | DB01177 | 552 | 77 | [
"DDInter302",
"DDInter904"
] | Carmustine | Idarubicin | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
552,
24,
77
]
],
[
[
552,
5,
11555
],
[
11555,
44,
77
]
],
[
[
552,
21,
28931
],
[
28931,
60,
77
]
],
[
[
552,
23,
646
],
[
646,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Carmustine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Diseas... | Carmustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Idarubicin (Compound)
Carmustine (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Compound)
Carmustine may cause a minor interaction that can limit clinical effects ... |
DB00762 | DB12887 | 613 | 1,598 | [
"DDInter973",
"DDInter1750"
] | Irinotecan | Tazemetostat | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
613,
24,
1598
]
],
[
[
613,
24,
985
],
[
985,
24,
1598
]
],
[
[
613,
63,
752
],
[
752,
24,
1598
]
],
[
[
613,
24,
466
],
[
466,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Ci... |
DB00694 | DB01263 | 51 | 859 | [
"DDInter485",
"DDInter1494"
] | Daunorubicin | Posaconazole | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
51,
24,
859
]
],
[
[
51,
6,
4973
],
[
4973,
45,
859
]
],
[
[
51,
21,
28762
],
[
28762,
60,
859
]
],
[
[
51,
23,
112
],
[
112,
23... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Daunorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Daunorubicin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole a... |
DB00831 | DB06603 | 1,178 | 39 | [
"DDInter1866",
"DDInter1387"
] | Trifluoperazine | Panobinostat | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1178,
25,
39
]
],
[
[
1178,
23,
112
],
[
112,
23,
39
]
],
[
[
1178,
24,
272
],
[
272,
24,
39
]
],
[
[
1178,
63,
506
],
[
506,
24... | [
[
[
"Trifluoperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorph... |
DB00569 | DB01138 | 553 | 804 | [
"DDInter775",
"DDInter1726"
] | Fondaparinux | Sulfinpyrazone | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Major | 2 | [
[
[
553,
25,
804
]
],
[
[
553,
25,
998
],
[
998,
1,
804
]
],
[
[
553,
64,
582
],
[
582,
24,
804
]
],
[
[
553,
25,
1274
],
[
1274,
24... | [
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylbutazone"
],
[
"Phenylbutazon... | Fondaparinux may lead to a major life threatening interaction when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Fondaparinux may lead to a major life threatening interaction when taken with Reteplase and Reteplase may cause a moderate interaction that could exacerbate dise... |
DB01149 | DB09122 | 851 | 1,613 | [
"DDInter1274",
"DDInter1409"
] | Nefazodone | Peginterferon beta-1a | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
851,
24,
1613
]
],
[
[
851,
63,
600
],
[
600,
24,
1613
]
],
[
[
851,
24,
1383
],
[
1383,
63,
1613
]
],
[
[
851,
25,
263
],
[
263,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Sodium s... |
DB01112 | DB09154 | 665 | 1,475 | [
"DDInter335",
"DDInter1686"
] | Cefuroxime | Sodium citrate | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
665,
24,
1475
]
],
[
[
665,
40,
1024
],
[
1024,
24,
1475
]
],
[
[
665,
63,
1096
],
[
1096,
24,
1475
]
],
[
[
665,
24,
115
],
[
115,
... | [
[
[
"Cefuroxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefpodoxime"
],
[
"Cefpodoxime",
"{u} may cause a m... | Cefuroxime (Compound) resembles Cefpodoxime (Compound) and Cefpodoxime may cause a moderate interaction that could exacerbate diseases when taken with Sodium citrate
Cefuroxime may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate in... |
DB06228 | DB12130 | 792 | 1,017 | [
"DDInter1609",
"DDInter1094"
] | Rivaroxaban | Lorlatinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
792,
24,
1017
]
],
[
[
792,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
792,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
792,
63,
409
],
[
409,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexa... |
DB01221 | DB09241 | 1,190 | 1,629 | [
"DDInter1007",
"DDInter1186"
] | Ketamine | Methylene blue | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Moderate | 1 | [
[
[
1190,
24,
1629
]
],
[
[
1190,
63,
1148
],
[
1148,
24,
1629
]
],
[
[
1190,
24,
659
],
[
659,
24,
1629
]
],
[
[
1190,
63,
73
],
[
73,
... | [
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vi... |
DB00539 | DB11110 | 11 | 603 | [
"DDInter1837",
"DDInter1115"
] | Toremifene | Magnesium citrate | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
11,
24,
603
]
],
[
[
11,
25,
57
],
[
57,
24,
603
]
],
[
[
11,
64,
789
],
[
789,
24,
603
]
],
[
[
11,
25,
484
],
[
484,
63,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Toremifene may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Toremifene may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may caus... |
DB00501 | DB01396 | 752 | 1,482 | [
"DDInter380",
"DDInter553"
] | Cimetidine | Digitoxin | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Minor | 0 | [
[
[
752,
23,
1482
]
],
[
[
752,
62,
1252
],
[
1252,
1,
1482
]
],
[
[
752,
6,
8374
],
[
8374,
45,
1482
]
],
[
[
752,
23,
1283
],
[
1283,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digitoxin"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Dig... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Cimetidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digitoxin (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects whe... |
DB00924 | DB01142 | 1,405 | 1,264 | [
"DDInter454",
"DDInter593"
] | Cyclobenzaprine | Doxepin | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
1405,
25,
1264
]
],
[
[
1405,
40,
508
],
[
508,
24,
1264
]
],
[
[
1405,
24,
401
],
[
401,
24,
1264
]
],
[
[
1405,
74,
832
],
[
832,
... | [
[
[
"Cyclobenzaprine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interact... | Cyclobenzaprine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction t... |
DB00275 | DB06691 | 217 | 849 | [
"DDInter1330",
"DDInter1155"
] | Olmesartan | Mepyramine | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
217,
24,
849
]
],
[
[
217,
63,
1648
],
[
1648,
24,
849
]
],
[
[
217,
24,
412
],
[
412,
63,
849
]
],
[
[
217,
24,
1376
],
[
1376,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Elu... |
DB00572 | DB01575 | 85 | 1,054 | [
"DDInter136",
"DDInter1005"
] | Atropine | Kaolin | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Moderate | 1 | [
[
[
85,
24,
1054
]
],
[
[
85,
63,
17
],
[
17,
23,
1054
]
],
[
[
85,
24,
772
],
[
772,
23,
1054
]
],
[
[
85,
24,
1592
],
[
1592,
62,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kaolin"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
],
[
"Sotalo... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a minor interaction that can limit clinical effects when taken with Kaolin
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a... |
DB00247 | DB00388 | 1,131 | 1,636 | [
"DDInter1194",
"DDInter1453"
] | Methysergide | Phenylephrine | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Major | 2 | [
[
[
1131,
25,
1636
]
],
[
[
1131,
25,
874
],
[
874,
40,
1636
]
],
[
[
1131,
21,
29083
],
[
29083,
60,
1636
]
],
[
[
1131,
25,
1466
],
[
14... | [
[
[
"Methysergide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylephrine"
]
],
[
[
"Methysergide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
... | Methysergide may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine (Compound) resembles Phenylephrine (Compound)
Methysergide (Compound) causes Mydriasis (Side Effect) and Mydriasis (Side Effect) is caused by Phenylephrine (Compound)
Methysergide may lead to a major life threateni... |
DB00333 | DB09054 | 576 | 384 | [
"DDInter1166",
"DDInter905"
] | Methadone | Idelalisib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
576,
24,
384
]
],
[
[
576,
24,
222
],
[
222,
23,
384
]
],
[
[
576,
40,
307
],
[
307,
23,
384
]
],
[
[
576,
25,
1618
],
[
1618,
2... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Methadone (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit cl... |
DB00470 | DB06717 | 530 | 875 | [
"DDInter601",
"DDInter778"
] | Dronabinol | Fosaprepitant | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
530,
24,
875
]
],
[
[
530,
24,
723
],
[
723,
1,
875
]
],
[
[
530,
21,
28734
],
[
28734,
60,
875
]
],
[
[
530,
24,
222
],
[
222,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Dronabinol (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Fosaprepitant (Compound)
Dronabinol m... |
DB00358 | DB01156 | 1,010 | 593 | [
"DDInter1140",
"DDInter252"
] | Mefloquine | Bupropion | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
1010,
25,
593
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1010,
21,
28757
],
[
28757,
60,
593
]
],
[
[
1010,
25,
996
],
[
996,
... | [
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropio... | Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Mefloquine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Mefloquine may lead to a major life threatening interaction when taken with Bedaquiline and Bedaquiline may caus... |
DB09038 | DB14730 | 1,450 | 1,412 | [
"DDInter636",
"DDInter264"
] | Empagliflozin | Calaspargase pegol | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1450,
24,
1412
]
],
[
[
1450,
63,
1144
],
[
1144,
24,
1412
]
],
[
[
1450,
24,
484
],
[
484,
24,
1412
]
],
[
[
1450,
63,
1510
],
[
1510... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Entre... |
DB00827 | DB06292 | 646 | 549 | [
"DDInter383",
"DDInter474"
] | Cinoxacin | Dapagliflozin | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
646,
24,
549
]
],
[
[
646,
24,
1344
],
[
1344,
40,
549
]
],
[
[
646,
21,
28787
],
[
28787,
60,
549
]
],
[
[
646,
64,
1179
],
[
1179,
... | [
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Cinoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Cinoxacin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Dapagliflozin (Compound)
Cinoxacin may lead to a major li... |
DB00694 | DB06643 | 51 | 1,136 | [
"DDInter485",
"DDInter500"
] | Daunorubicin | Denosumab | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
51,
24,
1136
]
],
[
[
51,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
51,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
51,
25,
1377
],
[
1377,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxal... |
DB00496 | DB01611 | 194 | 1,487 | [
"DDInter480",
"DDInter893"
] | Darifenacin | Hydroxychloroquine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
194,
24,
1487
]
],
[
[
194,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
194,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
194,
21,
28658
],
[
2865... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Darifenacin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Darifenacin (Co... |
DB04835 | DB14568 | 1,655 | 982 | [
"DDInter1125",
"DDInter1000"
] | Maraviroc | Ivosidenib | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1655,
24,
982
]
],
[
[
1655,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1655,
24,
1478
],
[
1478,
24,
982
]
],
[
[
1655,
24,
159
],
[
159,
... | [
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor m... |
DB01072 | DB15091 | 915 | 676 | [
"DDInter129",
"DDInter1901"
] | Atazanavir | Upadacitinib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
915,
25,
676
]
],
[
[
915,
25,
283
],
[
283,
24,
676
]
],
[
[
915,
23,
1374
],
[
1374,
24,
676
]
],
[
[
915,
24,
1040
],
[
1040,
... | [
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u}... | Atazanavir may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Atazanavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may caus... |
DB00812 | DB01099 | 998 | 1,272 | [
"DDInter1451",
"DDInter744"
] | Phenylbutazone | Flucytosine | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
998,
24,
1272
]
],
[
[
998,
24,
1448
],
[
1448,
24,
1272
]
],
[
[
998,
63,
599
],
[
599,
24,
1272
]
],
[
[
998,
1,
97
],
[
97,
2... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
... | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzu... |
DB06603 | DB10583 | 39 | 949 | [
"DDInter1387",
"DDInter415"
] | Panobinostat | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
39,
24,
949
]
],
[
[
39,
64,
1377
],
[
1377,
24,
949
]
],
[
[
39,
63,
58
],
[
58,
24,
949
]
],
[
[
39,
25,
1259
],
[
1259,
63,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {... | Panobinostat may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Panobinostat may cause a moderate interaction that could exacerbate disea... |
DB00261 | DB00983 | 702 | 480 | [
"DDInter93",
"DDInter776"
] | Anagrelide | Formoterol | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
702,
24,
480
]
],
[
[
702,
25,
1148
],
[
1148,
63,
480
]
],
[
[
702,
18,
10375
],
[
10375,
57,
480
]
],
[
[
702,
21,
29350
],
[
29350,... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprena... | Anagrelide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Anagrelide (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Formoterol (Compound)
Anagrelide (C... |
DB00214 | DB00348 | 1,028 | 254 | [
"DDInter1836",
"DDInter1300"
] | Torasemide | Nitisinone | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Moderate | 1 | [
[
[
1028,
24,
254
]
],
[
[
1028,
21,
29276
],
[
29276,
60,
254
]
],
[
[
1028,
24,
1144
],
[
1144,
63,
254
]
],
[
[
1028,
63,
600
],
[
600,... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
]
],
[
[
"Torasemide",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is ... | Torasemide (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Nitisinone (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with N... |
DB06605 | DB06717 | 1,409 | 875 | [
"DDInter108",
"DDInter778"
] | Apixaban | Fosaprepitant | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
1409,
24,
875
]
],
[
[
1409,
63,
723
],
[
723,
1,
875
]
],
[
[
1409,
21,
29122
],
[
29122,
60,
875
]
],
[
[
1409,
63,
222
],
[
222,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Apixaban (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Fosaprepitant (Compound)
Apixaban may cause a... |
DB00328 | DB12130 | 831 | 1,017 | [
"DDInter921",
"DDInter1094"
] | Indomethacin | Lorlatinib | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
831,
24,
1017
]
],
[
[
831,
24,
590
],
[
590,
24,
1017
]
],
[
[
831,
23,
450
],
[
450,
24,
1017
]
],
[
[
831,
25,
1421
],
[
1421,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Indomethacin may cause a minor interaction that can limit clinical effects when taken with Cyclophospham... |
DB00014 | DB00675 | 521 | 888 | [
"DDInter839",
"DDInter1744"
] | Goserelin | Tamoxifen | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
521,
24,
888
]
],
[
[
521,
24,
675
],
[
675,
25,
888
]
],
[
[
521,
24,
543
],
[
543,
63,
888
]
],
[
[
521,
5,
11579
],
[
11579,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperami... |
DB00960 | DB09564 | 887 | 1,296 | [
"DDInter1471",
"DDInter930"
] | Pindolol | Insulin degludec | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
887,
24,
1296
]
],
[
[
887,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
887,
25,
659
],
[
659,
24,
1296
]
],
[
[
887,
63,
104
],
[
104,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Pindolol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may ca... |
DB00405 | DB09076 | 128 | 1,116 | [
"DDInter517",
"DDInter1899"
] | Dexbrompheniramine | Umeclidinium | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
128,
24,
1116
]
],
[
[
128,
24,
849
],
[
849,
24,
1116
]
],
[
[
128,
63,
695
],
[
695,
24,
1116
]
],
[
[
128,
24,
337
],
[
337,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramin... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clo... |
DB06595 | DB11979 | 1,491 | 1,320 | [
"DDInter1214",
"DDInter625"
] | Midostaurin | Elagolix | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1491,
24,
1320
]
],
[
[
1491,
24,
1612
],
[
1612,
23,
1320
]
],
[
[
1491,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
1491,
63,
79
],
[
79,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Elagolix
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osil... |
DB00685 | DB09054 | 1,299 | 384 | [
"DDInter1887",
"DDInter905"
] | Trovafloxacin | Idelalisib | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1299,
24,
384
]
],
[
[
1299,
23,
328
],
[
328,
24,
384
]
],
[
[
1299,
63,
305
],
[
305,
24,
384
]
],
[
[
1299,
25,
891
],
[
891,
... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mercaptopurine"
],
... | Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Asparagin... |
DB12332 | DB15328 | 1,619 | 829 | [
"DDInter1626",
"DDInter1896"
] | Rucaparib | Ubrogepant | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1619,
24,
829
]
],
[
[
1619,
63,
1476
],
[
1476,
24,
829
]
],
[
[
1619,
64,
868
],
[
868,
24,
829
]
],
[
[
1619,
24,
1501
],
[
1501,
... | [
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Rucaparib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause ... |
DB00727 | DB09038 | 685 | 1,450 | [
"DDInter1304",
"DDInter636"
] | Nitroglycerin | Empagliflozin | Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure ex... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
685,
24,
1450
]
],
[
[
685,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
685,
24,
885
],
[
885,
24,
1450
]
],
[
[
685,
25,
1455
],
[
1455,
... | [
[
[
"Nitroglycerin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Nitroglycerin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
... | Nitroglycerin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Nitroglycerin may cause a moderate interaction that could exacerbate diseases when taken with Epoprost... |
DB01181 | DB09134 | 1,532 | 1,552 | [
"DDInter906",
"DDInter966"
] | Ifosfamide | Ioversol | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
1532,
25,
1552
]
],
[
[
1532,
63,
1648
],
[
1648,
24,
1552
]
],
[
[
1532,
24,
242
],
[
242,
63,
1552
]
],
[
[
1532,
63,
1448
],
[
1448... | [
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdes... |
DB01268 | DB11642 | 1,151 | 938 | [
"DDInter1731",
"DDInter1480"
] | Sunitinib | Pitolisant | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1151,
24,
938
]
],
[
[
1151,
62,
112
],
[
112,
23,
938
]
],
[
[
1151,
24,
760
],
[
760,
24,
938
]
],
[
[
1151,
63,
600
],
[
600,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobici... |
DB09054 | DB09237 | 384 | 1,586 | [
"DDInter905",
"DDInter1045"
] | Idelalisib | Levamlodipine | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
384,
24,
1586
]
],
[
[
384,
24,
466
],
[
466,
62,
1586
]
],
[
[
384,
64,
578
],
[
578,
23,
1586
]
],
[
[
384,
63,
1648
],
[
1648,
... | [
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Idelalisib may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may c... |
DB00365 | DB00836 | 839 | 543 | [
"DDInter842",
"DDInter1088"
] | Grepafloxacin | Loperamide | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
839,
24,
543
]
],
[
[
839,
25,
888
],
[
888,
24,
543
]
],
[
[
839,
24,
1478
],
[
1478,
63,
543
]
],
[
[
839,
25,
982
],
[
982,
6... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamox... | Grepafloxacin may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may caus... |
DB00519 | DB01276 | 1,638 | 123 | [
"DDInter1843",
"DDInter706"
] | Trandolapril | Exenatide | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1638,
24,
123
]
],
[
[
1638,
24,
708
],
[
708,
63,
123
]
],
[
[
1638,
24,
1573
],
[
1573,
24,
123
]
],
[
[
1638,
63,
1560
],
[
1560,
... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Prednisone a... |
DB01175 | DB08868 | 318 | 1,011 | [
"DDInter672",
"DDInter737"
] | Escitalopram | Fingolimod | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
318,
25,
1011
]
],
[
[
318,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
318,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
318,
24,
578
],
[
578,... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fin... | Escitalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Escitalopram (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Tic... |
DB00420 | DB11978 | 508 | 124 | [
"DDInter1532",
"DDInter822"
] | Promazine | Glasdegib | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
508,
24,
124
]
],
[
[
508,
23,
112
],
[
112,
23,
124
]
],
[
[
508,
64,
475
],
[
475,
24,
124
]
],
[
[
508,
63,
79
],
[
79,
24,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Promazine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a mod... |
DB00749 | DB01124 | 59 | 1,411 | [
"DDInter699",
"DDInter1828"
] | Etodolac | Tolbutamide | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
59,
24,
1411
]
],
[
[
59,
24,
959
],
[
959,
40,
1411
]
],
[
[
59,
63,
245
],
[
245,
40,
1411
]
],
[
[
59,
6,
10612
],
[
10612,
4... | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Et... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.